HB 3717 — Relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy.

HB 3717 (House Committee Report)

House Committee Report text of HB 3717.

89R14527 CJD-F

The document summary and details above are public. The full text is available to signed-in accounts.